Trial Profile
A randomized, open-label study of the addition of amantadine to PEGASYS [peginterferon alfa-2a] plus ribavirin on sustained virological response in patients with chronic hepatitis C viral infection who are treatment-naive or have experienced a relapse after treatment with interferon plus ribavirin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2010
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Amantadine; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Planned number of patients changed from 500 to 660 as reported by Roche record.
- 20 Aug 2008 Status change from recruiting to completed according to Roche protocol registry.
- 20 Jun 2006 New trial record.